You are here: Industry Insights > Zytiga

News List

NICE’s decision not to approve Zytiga ‘frustrating’, says ICR pharmatimes
July 16, 2021
The National Institute of Health and Care Excellence (NICE) has decided not to recommend Janssen’s Zytiga after reviewing its previous decision to reject the drug in 2020.
Erleada drug combination extends progression-free survival in prostate cancer trial europeanpharmaceuticalreview
February 10, 2021
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
NICE sticks to Zytiga rejection pharmatimes
June 29, 2020
NICE will not be recommending Janssen's Zytiga (abiraterone acetate) with prednisone or prednisolone plus androgen deprivation therapy (ADT), within its marketing authorisation , for treating newly diagnosed high-risk metastatic ...
Novel prostate cancer drug formulation could improve drug’s efficacy europeanpharmaceuticalreview
June 23, 2020
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
Dr Reddy’s Laboratories launch Abiraterone Acetate Tablets USP in the US expresspharma
June 22, 2020
Dr Reddy’s Laboratories announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga (abiraterone acetate) approved by the US Food and Drug Administration (USFDA).
Financial Report: Johnson & Johnson contractpharma
April 19, 2019
Pharmaceutical sales up 4% in the quarter despite declines for REMICADE and ZYTIGA.
J&J loses yet another fight to protect Zytiga from generics fiercepharma
November 27, 2018
Johnson & Johnson lost its latest effort to fend off Zytiga generics in court, sending investors reeling at the prospect of losing blockbuster sales. But the pharma giant says it’s now planning a last-ditch stand at the U.S. Supreme Court.
J&J shares fall after court refuses to block Zytiga generics pharmaphorum
November 27, 2018
Johnson & Johnson’s share price took a beating this week after the US appeals court declined its bid to stop sales of cheap generic versions of its blockbuster prostate cancer drug Zytiga.
US court overturns J&J's Zytiga patent in combination with prednisone pharmafile
October 31, 2018
A court in New Jersey has invalidated Johnson & Johnson’s patent on the prostate cancer drug Zytiga when used in combination with the steroid prednisone. ...
NICE rejects Janssen’s Zytiga for early, aggressive prostate cancer pharmatimes
July 06, 2018
It is looking unlikely that Janssen’s Zytiga plus androgen deprivation therapy (ADT) and prednisone/prednisolone will become routinely available on the NHS as a first-line treatment for patients with high-risk hormone-sensitive metastatic prostate cancer.

Previous page 1 2 Next page